**Question:** Mirrizi syndrome -

A. Cholestasis resulting from intrahepatic bile duct obstruction
B. Portal hypertension and esophageal varices without cholestasis
C. Cholestasis resulting from extrahepatic bile duct obstruction
D. Portal hypertension and esophageal varices without cholestasis

**Core Concept:** Mirrizi syndrome is a rare condition characterized by the coexistence of intrahepatic and extrahepatic bile duct obstructions. This can lead to two distinct clinical presentations: cholestasis and portal hypertension, respectively. The syndrome is named after Dr. Mirrizi, who first described it in 1939.

**Why the Correct Answer is Right:** In Mirrizi syndrome, the presence of both intrahepatic and extrahepatic bile duct obstructions causes two distinct clinical manifestations: cholestasis (A) and portal hypertension (D). Cholestasis results from intrahepatic bile duct obstructions (option A), while portal hypertension is caused by extrahepatic bile duct obstructions (option D). Cholestasis leads to elevated liver enzymes and pruritus, while portal hypertension presents with esophageal varices and ascites.

**Why Each Wrong Option is Incorrect:**

B. Cholestasis is not a significant feature in this scenario. Portal hypertension (option B) is primarily caused by intrahepatic (A) or extrahepatic (D) bile duct obstructions, not cholestasis.

C. Cholestasis is not a significant feature in this scenario. Portal hypertension (option C) is primarily caused by intrahepatic (A) or extrahepatic (D) bile duct obstructions, not cholestasis.

**Clinical Pearl:** Mirrizi syndrome is a crucial concept for postgraduate medical students studying hepatology and gastroenterology. Understanding this condition helps in differentiating it from other conditions like sclerosing cholangitis, where cholestasis is the main feature. Additionally, recognizing the clinical symptoms and signs associated with each component (cholestasis and portal hypertension) can guide appropriate diagnostic and management strategies, including imaging studies (e.g., MRCP or ERCP) and potential surgical or endoscopic interventions.